Surgery plus heated chemotherapy for recurrent mucinous ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies a planned surgery to remove as much cancer as possible, followed by heated chemotherapy placed in the belly (called HIPEC). It’s for people with recurrent mucinous ovarian cancer, aiming to control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your ovarian cancer has been proven by pathology as recurrent primary mucinous ovarian cancer
- You are age 18 or older
- Your daily functioning is limited at most mildly (ECOG 0–2)
- Your blood counts and organ tests are within safe ranges (neutrophils, platelets, liver/bilirubin, and kidney function)
- You are not too soon after chemo or radiation (more than 2 weeks; bevacizumab needs more than 6 weeks)
- You can sign informed consent and you can follow study visits and instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a special heated chemotherapy treatment during surgery (called HIPEC) improves outcomes for some people with ovarian, fallopian tube, or primary peritoneal cancer. It compares surgery alone versus surgery plus HIPEC after you’ve had chemotherapy first.
This trial looks at whether a heated chemotherapy treatment given in the abdomen during a planned second surgery (HIPEC) can improve outcomes for certain advanced ovarian cancers. It is for people who have already had initial chemotherapy and partially responded, with enough health to safely undergo surgery.
This trial tests if a second surgery to remove tumors, followed by heated chemotherapy in the abdomen, helps people with ovarian, fallopian tube, or peritoneal cancer whose cancer has returned while taking PARP inhibitor drugs.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests whether doing surgery with small incisions (minimally invasive) instead of a large cut is safe and effective for advanced ovarian cancer after chemo. It may mean a faster recovery while still removing the cancer.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.